Babak Baharloo
Podiatrist · Houston, TXNPI 1740662147
Payments from drug & device makers
Across 56 payments — averaging $135.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$3K
- Steelhead Surgical Inc$2K
- Integra Lifesciences Corporation$2K
- Kerecis Limited$800
- Smith+Nephew$163
- AbbVie$118
- plus $222 from 6 others
What the payments were for
- Travel & lodging$2,28130%
- Food & beverage$1,73323%
- Education$3,60047%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 19 | $2,552 |
| Steelhead Surgical Inc | 4 | $2,168 |
| Integra Lifesciences Corporation | 9 | $1,590 |
| Kerecis Limited | 3 | $800 |
| Smith+Nephew | 7 | $163 |
| AbbVie(2 entities) | 5 | $118 |
| Polarityte, Inc. | 1 | $96 |
| Biowound Solutions, Inc. | 3 | $66 |
| Osiris Therapeutics Inc. | 2 | $25 |
| Convatec Inc. | 1 | $12 |
| Amgen | 1 | $12 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BILAYER WOUND MATRIX (BWM)$865
- INTEGRA WOUND MATRIX (IWM)$865
- PRIMATRIX$865
- IDRT$865
- FLOWABLE$865
- Kerecis Omega3 GraftGuide$721
- Kerecis Omega3 SurgiClose$721
- SALTO TALARIS TOTAL ANKLE PROSTHESIS$639
- TOTAL FOOT SYSTEM$639
- CADENCE ANKLE REPLACEMENT SYSTEM$639
- Kerecis Omega3 Marigen$630
- Kerecis Omega3 Wound$511
- Kerecis Omega3 Surgibind$511
How this compares
$7,614 in reported general payments places this provider in the 75th percentile of 470 podiatrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 214 | $2,061 |
| Triamcinolone Acetonide | 63 | $1,717 |
| Mupirocin | 72 | $1,318 |
| Cefdinir | 34 | $591 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 27 | $290 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 37 | $273 |
| Levofloxacin | 34 | $271 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $194 |
| Fluconazole | 11 | $126 |
| Meloxicam | 23 | $61 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Houston
- Gary LepowHouston$1M
- Andrew SchneiderHouston$179K
- Gabriel MaislosHouston$140K
- Randall BeckmanHouston$104K
- Jason ArmstrongHouston$91K
- Smitha ManthaHouston$69K
- Jerry MilesHouston$58K
- Tina OliverHouston$42K
- Lawrence MactavishHouston$41K
- Roberto de Los SantosHouston$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.